On March 22, 2000, Vancouver-based Angiotech Pharmaceuticals, Inc. (Angiotech), which develops and intends to commercialize new treatments for chronic inflammatory diseases such as restenosis, multiple sclerosis, rheumatoid arthritis and psoriasis, closed a $138 million cross-border offering—one of the largest biotech offerings ever completed in Canada. The common shares were offered in Canada and the U.S. using the Canada/U.S. securities regulators Multijurisdictional Disclosure System. The US portion of the deal was underwritten by Deutsche Banc Securities, Inc., Merrill Lynch Inc. and U.S. Bancorp Piper Jaffray Inc. The Canadian component was underwritten by the Canadian affiliates of Deutsche Banc Securities, Inc. and Merrill Lynch Inc. together with Loewen, Ondaatje, McCutcheon Ltd. and Yorkton Securities Inc.
The Blake, Cassels & Graydon LLP team of Geoffrey Belsher and Bob Wooder in Vancouver advised the underwriters and were assisted by a Morrison & Foerster LLP New York team led by Jeffrey Marcus. David Jennings of Irwin, White & Jennings in Vancouver and Matthew Topham of Preston Gates & Ellis LLP of Seattle represented Angiotech.
The Blake, Cassels & Graydon LLP team of Geoffrey Belsher and Bob Wooder in Vancouver advised the underwriters and were assisted by a Morrison & Foerster LLP New York team led by Jeffrey Marcus. David Jennings of Irwin, White & Jennings in Vancouver and Matthew Topham of Preston Gates & Ellis LLP of Seattle represented Angiotech.
